Stroke and Myocardial Infarction in Patients with Abdominal Aortic Aneurysm and New-Onset Atrial Fibrillation

Chalotte W. Nicolajsen; Peter B. Nielsen; Martin Jensen; Nikolaj Eldrup; Torben B. Larsen; Gregory Y. H. Lip; Samuel Z. Goldhaber; Mette Søgaard

doi:10.1055/a-2009-8954

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2023; 123(05): 555-564
DOI: 10.1055/a-2009-8954

Atherosclerosis and Ischaemic Disease

Stroke and Myocardial Infarction in Patients with Abdominal Aortic Aneurysm and New-Onset Atrial Fibrillation

Chalotte W. Nicolajsen

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

²Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

³Department of Vascular Surgery, Viborg Regional Hospital, Viborg, Denmark

,

Peter B. Nielsen

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

²Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

,

Martin Jensen

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

,

Nikolaj Eldrup

⁴Department of Vascular Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

⁵Copenhagen University, Copenhagen, Denmark

,

Torben B. Larsen

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

²Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

,

Gregory Y. H. Lip

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

⁶Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

,

Samuel Z. Goldhaber

⁷Division of Cardiovascular Medicine, Thrombosis Research Group, Brigham and Women's Hospital, Boston, Massachusetts, United States

⁸Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States

,

Mette Søgaard

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

²Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

› Author Affiliations

Abstract

Objective We investigated the association between new-onset atrial fibrillation (AF) and risk of stroke and myocardial infarction (MI) in patients with abdominal aortic aneurysmal (AAA) disease.

Methods Observational crossover study using Danish nationwide data, including patients with AAA and incident AF between 1997 and 2018. We estimated the 1-year risk of stroke and MI and the within-individual odds ratios (ORs) of ischemic events before and after an AF diagnosis, stratified by year of AF diagnosis (1997–2010 and 2011–2018), and supplemented with analyses on changes in use of antithrombotic therapy.

Results A total of 3,035 AAA patients were included: 1,040 diagnosed during 1997 to 2010, and 1,995 during 2011 to 2018 (22.2% females, median age 78 years; median CHA₂DS₂-VASc score 4; interquartile range: 3–5). One-year risk of ischemic events after AF was 5.9% (confidence interval [CI] 95%: 4.6–7.5%) and 4.5% (CI 95%: 3.7–5.5%) for stroke and 5.4% (CI 95%: 4.2–6.9%) and 4.0% (CI 95%: 3.2–4.9%) for MI during 1997 to 2010 and 2011 to 2018, respectively. The OR of ischemic stroke before and after incident AF was 2.8 (CI 95%: 1.6–5.2) during 1997 to 2010; and 2.4 (CI 95%: 1.5 to 3.9) during 2011 to 2018, and 3.5 (CI 95%: 1.7–7.5) and 1.5 (CI 95%: 0.9–2.4) for MI. One-year proportion of prescription claims for oral anticoagulants after AF changed from 66.1% in 1997 to 2010 to 82.6% in 2011 to 2018, while antiplatelet prescription claims changed from 80.8 to 60.9%.

Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and MI.

Keywords

aortic aneurysm - abdominal - atrial fibrillation - stroke - myocardial infarction - risk assessment

Full Text

References

References
1 Eldrup N, Budtz-Lilly J, Laustsen J, Bibby BM, Paaske WP. Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms. J Vasc Surg 2012; 55 (02) 311-317
2 Bahia SS, Holt PJE, Jackson D. et al. Systematic review and meta-analysis of long-term survival after elective infrarenal abdominal aortic aneurysm repair 1969-2011: 5 year survival remains poor despite advances in medical care and treatment strategies. Eur J Vasc Endovasc Surg 2015; 50 (03) 320-330
3 Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 2017; 120 (09) 1501-1517
4 Hindricks G, Potpara T, Germany ND. et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42 (05) 373-498
5 Bassand JP, Virdone S, Goldhaber SZ. et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation 2019; 139 (06) 787-798
6 Miao B, Hernandez AV, Roman YM, Alberts MJ, Coleman CI, Baker WL. Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. Clin Cardiol 2020; 43 (05) 524-531
7 Vrsalović M, Presečki AV. Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: a meta-analysis of prospective studies. Clin Cardiol 2017; 40 (12) 1231-1235
8 Aguilar E, García-Díaz AM, Sánchez Muñoz-Torrero JF. et al; FRENA Investigators. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. Thromb Res 2012; 130 (03) 390-395
9 da Silva RMFL. Influence of inflammation and atherosclerosis in atrial fibrillation. Curr Atheroscler Rep 2017; 19 (01) 2
10 Peshkova IO, Schaefer G, Koltsova EK. Atherosclerosis and aortic aneurysm - is inflammation a common denominator?. FEBS J 2016; 283 (09) 1636-1652
11 Nicolajsen CW, Søgaard M, Eldrup N. et al. Temporal trends in abdominal aortic aneurysmal disease: a nationwide cohort study on cardiovascular morbidity and medical cardioprotective therapy. Eur J Prev Cardiol 2022; 29 (15) 1957-1964
12 Bahia SS, Vidal-Diez A, Seshasai SR. et al. Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. Br J Surg 2016; 103 (12) 1626-1633
13 Lip GYH, Ntaios G. “Novel Clinical Concepts in Thrombosis”: integrated care for stroke management-easy as ABC. Thromb Haemost 2022; 122 (03) 316-319
14 Wanhainen A, Verzini F, Van Herzeele I. et al; Esvs Guidelines Committee. Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg 2019; 57 (01) 8-93
15 Perreault S, de Denus S, White-Guay B. et al. Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation. Pharmacotherapy 2020; 40 (01) 40-54
16 Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449-490
17 Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 2017; 46 (03) 798-798f
18 Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29 (08) 541-549
19 Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012; 46 (03) 149-153
20 Sundbøll J, Adelborg K, Munch T. et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 2016; 6 (11) e012832
21 Redelmeier DA. The exposure-crossover design is a new method for studying sustained changes in recurrent events. J Clin Epidemiol 2013; 66 (09) 955-963
22 Cadarette SM, Maclure M, Delaney JAC. et al. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2021; 30 (06) 671-684
23 Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137 (02) 263-272
24 Aboyans V, Bauersachs R, Mazzolai L. et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J 2021; 42 (39) 4013-4024
25 Rosenblatt M. Remarks on some nonparametric estimates of a density function. Ann Math Stat 1956; 27 (03) 832-837
26 Bath MF, Saratzis A, Saedon M, Sidloff D, Sayers R, Bown MJ. UKAGS investigators. Patients with small abdominal aortic aneurysm are at significant risk of cardiovascular events and this risk is not addressed sufficiently. Eur J Vasc Endovasc Surg 2017; 53 (02) 255-260
27 Conway DSG, Lip GYH. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 2004; 93 (11) 1422-1425 , A10
28 Field M, Kuduvalli M, Torella F, McKay V, Khalatbari A, Lip GYH. Integrated care systems and the aortovascular hub. Thromb Haemost 2022; 122 (02) 177-180
29 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
30 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
31 Masunaga N, Abe M, Ogawa H. et al; Fushimi AF Registry Investigators. Current status, time trends and outcomes of combination therapy with oral anticoagulant and antiplatelet drug in patients with atrial fibrillation—The fushimi AF registry—. Circ J 2018; 82 (12) 2983-2991
32 Lodziński P, Gawałko M, Budnik M. et al. Trends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry. Pol Arch Intern Med 2020; 130 (03) 196-205
33 Wändell P, Carlsson AC, Holzmann MJ. et al. Warfarin treatment and risk of myocardial infarction - a cohort study of patients with atrial fibrillation treated in primary health care. Int J Cardiol 2016; 221 (221) 789-793
34 Tonnesen P, Marott JL, Nordestgaard B, Bojesen SE, Lange P. Secular trends in smoking in relation to prevalent and incident smoking-related disease: a prospective population-based study. Tob Induc Dis 2019; 17 (October): 72
35 Persson SE, Boman K, Wanhainen A, Carlberg B, Arnerlöv C. Decreasing prevalence of abdominal aortic aneurysm and changes in cardiovascular risk factors. J Vasc Surg 2017; 65 (03) 651-658
36 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
37 Rohla M, Weiss TW, Pecen L. et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open 2019; 9 (03) e022478
38 Maeda T, Nishi T, Funakoshi S. et al. Residual risks of ischaemic stroke and systemic embolism among atrial fibrillation patients with anticoagulation: large-scale real-world data (F-CREATE project). Heart 2021; 107 (03) 217-222
39 Kim YG, Choi JIL, Boo KY. et al. Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation. Clin Cardiol 2020; 43 (01) 78-85
40 Wallenhorst C, Martinez C, Freedman B. Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally detected in primary care compared with other clinical presentations. Thromb Haemost 2022; 122 (02) 277-285
41 Sun W, Freedman B, Martinez C, Wallenhorst C, Yan BP. Atrial fibrillation detected by single time-point handheld electrocardiogram screening and the risk of ischemic stroke. Thromb Haemost 2022; 122 (02) 286-294
42 Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 2021; 16 (02) 217-221
43 Hsu CC, Chien WC, Wang JC. et al. Association between atrial fibrillation and aortic aneurysms: a population-based cohort study. J Vasc Res 2018; 55 (05) 299-307

Supplementary Material

Supplementary Material